Cardiovascular & Renal Pharmacology Foundations

Core concept: Most cardiovascular and renal medications work by changing vascular resistance, intravascular volume, venous return, heart rate, contractility, neurohormonal activation, renal sodium handling, cardiac electrophysiology, or atherosclerotic risk.

Key clinical distinction: Improving a physiologic number or symptom does not necessarily reduce hospitalization, kidney events, stroke, or mortality.

Prescribing priority: Identify the physiologic problem and the outcome being targeted, then select therapy according to ventricular function, kidney function, electrolytes, blood pressure, heart rate/rhythm, comorbidities, and concurrent medications.

Start With the Hemodynamics

Blood pressure is determined primarily by cardiac output and systemic vascular resistance. Cardiac output is the product of heart rate and stroke volume; stroke volume is influenced by preload, afterload, contractility, and ventricular compliance. Cardiovascular drugs therefore change blood pressure and cardiac workload by modifying one or more of these variables (Williams et al., 2026).

Preload reflects ventricular filling and is strongly influenced by venous return and intravascular volume. Diuretics reduce total-body sodium and water, while venodilators such as nitrates reduce venous return. Both can lower filling pressure, but excessive preload reduction can cause hypotension and organ hypoperfusion.

Afterload is the resistance against which the ventricle ejects. Arteriolar vasodilators, RAAS inhibitors, and dihydropyridine calcium channel blockers can reduce systemic vascular resistance. Heart rate and contractility affect both cardiac output and myocardial oxygen demand; beta blockers and nondihydropyridine calcium channel blockers can reduce both (Landup & Havrda, 2026).

The Kidney Is Part of Cardiovascular Pharmacology

The kidney is a major regulator of extracellular volume and blood pressure. Reduced renal perfusion, sympathetic stimulation, or reduced sodium delivery to the macula densa promotes renin release. Angiotensin II increases vascular tone, while aldosterone promotes sodium retention. Together, these responses form the renin-angiotensin-aldosterone system (RAAS). They can support short-term perfusion but become maladaptive when chronically activated in hypertension and heart failure (Williams et al., 2026; Ng & Yeung, 2026).

ACE inhibitors reduce angiotensin II formation. Angiotensin receptor blockers (ARBs) block AT1-receptor signaling. Mineralocorticoid receptor antagonists (MRAs) block aldosterone signaling. Sacubitril/valsartan adds neprilysin inhibition to angiotensin-receptor blockade, augmenting natriuretic-peptide activity. Sodium-glucose cotransporter 2 (SGLT2) inhibitors modify proximal tubular sodium and glucose handling and have cardiac and renal benefits beyond glucose lowering (Ng & Yeung, 2026).

Cardiorenal Prescribing Safety

Renal function is both a treatment target and a dosing variable. RAAS inhibitors alter glomerular hemodynamics; a modest early decline in filtration after starting an ACE inhibitor or ARB can reflect expected efferent arteriolar dilation rather than tubular injury. A sudden creatinine rise of more than 30% above the pretreatment value, uncontrolled hyperkalemia, or symptomatic hypotension should prompt reassessment of volume status, interacting medications, renovascular disease, and the regimen. Diuretic response also depends partly on drug delivery to the tubular lumen, while drugs such as digoxin, sotalol, dofetilide, and several anticoagulants require kidney-function-based dosing or monitoring. Use the renal metric specified for the medication rather than assuming estimated glomerular filtration rate (eGFR) and creatinine clearance are interchangeable (Williams et al., 2026; Ng & Yeung, 2026; Parker & Coons, 2026).

Potassium is a cross-cutting safety signal. ACE inhibitors, ARBs, ARNIs, MRAs, epithelial sodium channel (ENaC) blockers, and potassium supplements can increase potassium; loop and thiazide diuretics can lower potassium and magnesium. Nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce renal perfusion and blunt the effect of diuretics and antihypertensives. Medication reconciliation, volume assessment, renal function, and electrolytes are therefore part of the pharmacodynamic assessment—not merely laboratory surveillance (Williams et al., 2026; Ng & Yeung, 2026).

2026 CKM Cardiorenal Integration

The 2026 AHA/ACC/ADA/ASN cardiovascular-kidney-metabolic (CKM) guideline treats metabolic risk, chronic kidney disease, and cardiovascular disease as interdependent rather than siloed conditions. Characterize chronic kidney disease with both estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), because albuminuria changes kidney and cardiovascular risk even when filtration is relatively preserved (American Heart Association, 2026).

For appropriate patients with chronic kidney disease plus type 2 diabetes or albuminuric chronic kidney disease, renin-angiotensin system inhibition and SGLT2 inhibition are foundational kidney- and cardiovascular-protective therapies. When albuminuria persists in chronic kidney disease with type 2 diabetes, a nonsteroidal mineralocorticoid receptor antagonist or glucagon-like peptide-1 (GLP-1)-based therapy may provide additional protection. Heart failure, chronic kidney disease, obesity, diabetes, and atherosclerotic cardiovascular disease should therefore be managed as an integrated CKM phenotype rather than as unrelated problems (American Heart Association, 2026).

Major Drug-Class Effects

Renin-Angiotensin System Inhibitors

ACE inhibitors and ARBs reduce RAAS-mediated vasoconstriction and aldosterone activity. Their value extends beyond blood-pressure reduction because RAAS inhibition can modify cardiovascular and renal outcomes in selected patients with hypertension, CKD, HFrEF, and coronary disease. ACE inhibitors can cause bradykinin-mediated cough and angioedema; both ACE inhibitors and ARBs can increase potassium and change renal function. ACE inhibitor + ARB combination therapy is not recommended (Williams et al., 2026).

Beta-Adrenergic Blockade

Beta1 blockade decreases heart rate, myocardial contractility, and renin release. These effects can lower myocardial oxygen demand, treat selected tachyarrhythmias, reduce blood pressure, and counter maladaptive sympathetic activation. Beta blockers are not interchangeable across indications: carvedilol, metoprolol succinate, and bisoprolol have established HFrEF outcome benefit, while antianginal and rate-control use depends on hemodynamics and rhythm (Ng & Yeung, 2026; Parker & Coons, 2026).

Beta-blocker properties also affect selection. Metoprolol and bisoprolol are relatively beta1-selective at lower doses, whereas propranolol and nadolol are nonselective; carvedilol and labetalol add alpha1 blockade. Beta1 selectivity diminishes as dose increases. Chronic beta-blocker therapy should not be stopped abruptly because rebound sympathetic activity can precipitate hypertension or ischemic symptoms; taper when clinically feasible (Williams et al., 2026).

Calcium Channel Blockers

Dihydropyridine calcium channel blockers (CCBs) such as amlodipine act predominantly on vascular smooth muscle and reduce arterial resistance. Nondihydropyridines—verapamil and diltiazem—also slow AV-node conduction and reduce contractility. This difference drives selection: a dihydropyridine can lower BP without substantial rate slowing, whereas a nondihydropyridine can provide rate control but may worsen bradycardia, conduction disease, or HFrEF. Dihydropyridines commonly cause dependent peripheral edema through preferential arteriolar/precapillary vasodilation; this finding does not automatically indicate systemic sodium and water overload (Williams et al., 2026; Parker & Coons, 2026).

Diuretics and Sodium Handling

Diuretics increase renal sodium excretion at different nephron sites. Thiazide/thiazide-like agents are important antihypertensive drugs; loop diuretics are the principal agents for clinically significant congestion. Potassium-sparing ENaC blockers and MRAs have distinct therapeutic roles despite both increasing hyperkalemia risk. Detailed nephron-site pharmacology and decongestion decisions are addressed on the Diuretics & Volume Management page (Williams et al., 2026; Ng & Yeung, 2026).

Nitrates and Other Vasodilators

Nitrates primarily dilate veins at typical antianginal doses, reducing venous return and myocardial wall tension; higher exposure also reduces afterload. Hydralazine and minoxidil are direct arteriolar vasodilators used selectively because reflex sympathetic activation and sodium retention can complicate treatment (Williams et al., 2026; Landup & Havrda, 2026).

Electrophysiologic Drugs

Antiarrhythmic drugs alter conduction velocity, automaticity, refractoriness, or AV-node conduction. Their safety depends heavily on the arrhythmia, structural heart disease, LVEF, QT interval, electrolytes, kidney function, and drug interactions. Rate control, rhythm control, and stroke prevention are separate therapeutic goals in atrial fibrillation (Parker & Coons, 2026).

Lipid-Lowering Therapy Changes Risk Rather Than Hemodynamics

Statins and other lipid-lowering therapies primarily modify atherosclerotic risk rather than preload, afterload, heart rate, or contractility. Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, reduce hepatic cholesterol synthesis, and increase LDL-receptor activity. Treatment intensity is determined by ASCVD risk and the magnitude of LDL lowering required, not simply whether a value falls outside the laboratory reference range (Marrs & Kostoff, 2026).

Separate Symptom Control From Disease Modification

A loop diuretic may rapidly improve congestion without replacing HFrEF disease-modifying therapy. Nitroglycerin can relieve ischemic symptoms without providing the same long-term event reduction as lipid-lowering or antiplatelet therapy. A rate-control drug can improve palpitations without addressing AF-related thromboembolic risk. The prescribing question is therefore not only “Does this drug change the number?” but also “Does it improve the outcome that matters for this patient?”

High-Yield Distinctions

  • Dihydropyridine CCBs primarily vasodilate; verapamil and diltiazem also slow AV conduction and reduce contractility.
  • Beta blockers are not routine first-line therapy for uncomplicated hypertension; beta1 selectivity, alpha1 blockade, pulmonary disease, and withdrawal risk can influence selection and counseling.
  • ACE inhibitors and ARBs should not routinely be combined.
  • Diuretics manage sodium, water, and congestion; the class and dose depend on the treatment goal and kidney function.
  • Potassium and renal function are shared safety variables across several cardiorenal drug classes.
  • Antiarrhythmic selection changes when structural heart disease, HFrEF, QT prolongation, or kidney dysfunction is present.
  • SGLT2 inhibitors are cardiorenal drugs, not simply diabetes medications.
  • Statins reduce atherosclerotic risk rather than directly changing hemodynamics.
  • The 2026 CKM framework uses both eGFR and UACR to characterize kidney risk and integrates kidney-, metabolic-, and cardiovascular-protective therapy.
  • Dihydropyridine CCB edema reflects precapillary vasodilation and should not automatically be treated as systemic volume overload.

Related YourDNP Resources

Content last reviewed:

References

American Heart Association. (2026, June 9). Top things to know: 2026 guideline for the prevention, detection, evaluation, and management of CKM syndrome. https://professional.heart.org/en/science-news/2026-guideline-for-the-prevention-detection-evaluation-and-management-of-ckm-syndrome/top-things-to-know

Landup, D., & Havrda, D. (2026). Chronic coronary disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 239–275). McGraw Hill.

Marrs, J. C., & Kostoff, M. D. (2026). Dyslipidemia. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 478–524). McGraw Hill.

Ng, T. M. H., & Yeung, S. L. (2026). Heart failure. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 184–238). McGraw Hill.

Parker, R. B., & Coons, J. C. (2026). Arrhythmias. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 327–386). McGraw Hill.

Williams, C., Finks, S. W., & Chisholm-Burns, M. A. (2026). Hypertension. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 139–183). McGraw Hill.